A new preclinical study shows promising results for OXC-101 (TH1579) as a treatment for psoriasis. The study was conducted in collaboration with Professor Charlotta Enerbäck at Linköping University and Oxcia. Charlotta Enerbäck is professor of dermatology at Linköping University, clinical active, belongs to several advisory boards in psoriasis and is a board member of the European Dermatology Forum.
Topical application of OXC-101 effectively inhibits several hallmarks of psoriasis, including keratinocyte hyperproliferation and infiltration of IL-17-producing γδ-T cells. The levels of key cytokines involved in the inflammatory response in psoriatic skin were also reduced. The underlying mechanism involves the MTH1-SKP2-WNT5a signaling pathway.
Oxcia’s CEO, Ulrika Warpman Berglund, comments: “These additional data for OXC-101 show that the compound targets pathways crucial to the development and progression of the disease, and has the potential to become an innovative treatment for psoriasis in a tolerable and easy-to-use topical formulation.”
Charlotta Enerbäck, Professor of Dermatology at Linköping University, comments: "Most psoriasis patients have mild to moderate disease, for which systemic treatments are not motivated. There are still few treatment options available for this large group, and a new effective topical treatment would therefore be a very welcome addition."
Psoriasis is a chronic, immune-mediated skin disease affecting 2–3% of the global population. It is characterized by excessive cell proliferation, inflammation, and metabolic disturbances—traits it shares with cancer. Increased production of reactive oxygen species (ROS) and a compromised antioxidant system play a key role in the disease’s pathogenesis.
Oxcia has entered a research collaboration with LEO Pharma to explore topical formulations of OXC-101 for medical dermatology indications, including psoriasis. In oncology, specifically acute myeloid leukemia (AML), Oxcia is conducting a Phase I/II expansion study in a selected group of patients with relapsed/recurrent AML. The company has also received Orphan Drug Designation (ODD) from the FDA for AML.
The study was recently published in the highly regarded journal IJMS. For more information, visit:
🔗 https://www.mdpi.com/1422-0067/26/15/7174
For more information contact:
Ulrika Warpman Berglund, CEO, Oxcia AB (publ)
Telephone: +46 (0) 73 270 9605
ulrika.warpmanberglund@oxcia.com
Briefly about Oxcia AB
Oxcia’s aim is to improve and extend lives by developing new innovative treatments based on our unique technology platform, O2-DDR. Oxcia AB is a pioneer in oxidative DNA damage and DNA Damage Response (DDR – the processes the body uses to repair the damage that occurs to DNA) with a focus on developing new safe and effective treatments for patients suffering from diseases caused by cancer or inflammation. Oxcia currently has two O2-DDR lead drug candidates, both with the potential to become first-in-class drugs. OXC-101 is in early clinical development as novel cancer therapy. OXC-201 is developed against idiopathic pulmonary fibrosis, and is in the preclinical phase. The portfolio also includes exploratory projects, e.g in psoriasis.
More information about Oxcia is available at www.oxcia.com